Vascular Endothelial Growth Factor Gene Polymorphisms and Vitreous Proteome Changes in Diabetic Retinopathy

References

• Al-Latayfeh M. Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006411
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor. European Journal of Cancer. 1996; 32A:2413–2422
   PubMed Web of Science ®Google Scholar
• Mbanya JC. Global Diabetes Plan 2011–2021, Brussels, Belgium: International Diabetes Federation, 2011
   Google Scholar
• Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: The Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126(12):1707–1715
   PubMedGoogle Scholar
• Abhary S, Burdon KB. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2009;50:5552–5558
   PubMed Web of Science ®Google Scholar
• Al-Kateb H, Mirea L. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes. 2007;56:2161–2168
   PubMed Web of Science ®Google Scholar
• Aiello LP, Ferrara N, King GL. Hypoxic regulation and bioactivity of vascular endothelial growth factor: Characterization in retinal microvascular pericytes and pigment epithelial cells. Invest Ophthalmol Vis Sci. 1994;35:1868–1868
   Google Scholar
• Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retiopathy. Ophthalmol Clin N Am. 2002;15:69–79
   PubMedGoogle Scholar
• Senger DR. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 1986;46:5629–5632
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine. 1994;331:1480–1487
   PubMed Web of Science ®Google Scholar
• Tolentina MJ. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmol 1996;103:1820–1828
   PubMedGoogle Scholar
• Tolentina MJ. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol. 1996;114:964–970
   PubMedGoogle Scholar
• Adamis AP, Miller JW. Vascular permeability factor (vascular endothelial growth factor) is produced in the retina and elevated levels are present in the aqueous humor of eyes with iris neovascularization. Invest Ophthalmol Vis Sci. 1993;34:1440–1440
   Web of Science ®Google Scholar
• Adamis AP, Miller JW. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–450
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Pro Natl Acad Sci USA. 1995;92:10457–10461
   PubMed Web of Science ®Google Scholar
• Robinson GS, Pierce EA. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93(10):4851–4856
   PubMedGoogle Scholar
• Miller JW, Adamis AP. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574–584
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801
   PubMed Web of Science ®Google Scholar
• Bandello, MP. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625
   PubMedGoogle Scholar
• Kaines, MM. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117(6):1078–1086
   PubMedGoogle Scholar
• Avery RL, Pearlman J. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1–15
   Google Scholar
• Ford KM, D’Amore PA. Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium. Molecular Vision. 2012;18:519–527
   PubMed Web of Science ®Google Scholar
• Takagi H, King GL, Robinson GS, et al. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest Ophthalmol Vis Sci. 1996;37(11):2165–2176
   PubMedGoogle Scholar
• Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci. 1996;37(7):1311–1321
   PubMed Web of Science ®Google Scholar
• Szaflik JP, Wysocki T. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:39–43
   PubMed Web of Science ®Google Scholar
• Yang Y, Andresen BT. Association of vascular endothelial growth factor −634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Experimental Biology and Medicine. 2010;235:1204–1211
   Google Scholar
• Suganthalakshmi B. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006;12:336–341
   PubMed Web of Science ®Google Scholar
• Awata T, Inoue K. A common polymorphism in the 5’-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635–1639
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhao J. Association between the −634 C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice. 2010;90:45–53
   PubMed Web of Science ®Google Scholar
• Nakamura S, Iwasaki N. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:21–26
   PubMed Web of Science ®Google Scholar
• Chun MY, Hwang HS. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2010;95(7):3547–3551
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Watanabe C. Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. Clinica Chimica Acta. 2009;402:171–175
   PubMedGoogle Scholar
• Yang X, Deng Y. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Molecular Vision. 2011;17:3088–3096
   PubMed Web of Science ®Google Scholar
• Churchill AJ, Carter JG. VEGF polymorphisms are associated with severity of diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2008;49:3611–3616
   PubMedGoogle Scholar
• Liew G, Klein R. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49(2):35–52
   PubMedGoogle Scholar
• Steven A. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812–816
   PubMedGoogle Scholar
• Ray D, Mishra M. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004;53(3):861–864
   PubMedGoogle Scholar
• Ma, Y., Zhang, Y. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bavacizumab. American Journal of Ophthalmology. 2012;153:307–313
   PubMed Web of Science ®Google Scholar
• Praidou, A., Papakonstantinou, E. Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macular oedema. Acta Ophthalmologica. 2011;89:248–254
   PubMed Web of Science ®Google Scholar
• Shimada H. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Investigative Ophthalmology and Visual Science. 2009;50:2953–2955
   PubMed Web of Science ®Google Scholar
• Funatsu H. Vitreous level of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113:294–301
   PubMed Web of Science ®Google Scholar
• Bernardi R. PML inhibits HIF-1a translation and neoangiogenesis through repression of mTOR. Nature. 2006; 442:779–785
   PubMed Web of Science ®Google Scholar
• Katome, T. Expression of promyelocytic leukemia protein and vascular endothelial growth factor in aqueous humor and vitreous fluid in patients with proliferative diabetic retinopathy. Diabetes Research and Clinical Practice. 2012;98:e9–e11
   Google Scholar
• Gao BB, Clermont A. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Medicine. 2007;13:181–188
   PubMed Web of Science ®Google Scholar
• Gao BB, Chen X. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. Journal of Proteome Research. 2008;7:2516–2525
   PubMed Web of Science ®Google Scholar